The submitting of the IND follows a successful Pre-IND meeting with the FDA.

Collegium Pharmaceutical documents IND for second opioid item using DETERx technology Collegium Pharmaceutical, Inc. The submitting of the IND follows a successful Pre-IND meeting with the FDA, where guidance was provided to the ongoing company regarding the foundation of approval and the merchandise development plan www .2 million new nonmedical users aged 12 or old in 2008. The same publication also reported that the problem proceeds to grow in the US. From 2002 to 2008, the rate of current nonmedical usage of prescription pain relievers had elevated among young adults aged 18 to 25.